Indication
Metastatic Triple-negative Breast Cancer
3 clinical trials
3 products
3 drugs
Product
Sacituzumab GovitecanClinical trial
A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsStatus: Active (not recruiting), Estimated PCD: 2021-08-06
Clinical trial
Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by PembrolizumabStatus: Completed, Estimated PCD: 2022-07-22
Product
ADV/HSV-tkProduct
ValacyclovirDrug
mFOLFOX6Clinical trial
A Multicenter, Open-label, Single-arm Study of Surufatinib in Combination With Tislelizumab for Second-line and Further Treatment of Metastatic Triple-negative Breast Cancer (TNBC)Status: Not yet recruiting, Estimated PCD: 2024-08-01
Drug
TiragolumabDrug
PD-1 antibody